Cellular and T cell engager Immunotherapy
Evaluating T-cell fitness pre B-cell maturation antigen (BCMA)-targeted T-cell redirection therapies (TRT) as a predictive marker for efficacy/toxicity in relapsed/refractory multiple myeloma (RRMM)
Poy Theprungsirikul, MD
Clinical Fellow
Yale School of Medicine, United States